CN103446403A - Traditional Chinese medicine preparation for treating polycystic ovarian syndrome - Google Patents
Traditional Chinese medicine preparation for treating polycystic ovarian syndrome Download PDFInfo
- Publication number
- CN103446403A CN103446403A CN2013104222919A CN201310422291A CN103446403A CN 103446403 A CN103446403 A CN 103446403A CN 2013104222919 A CN2013104222919 A CN 2013104222919A CN 201310422291 A CN201310422291 A CN 201310422291A CN 103446403 A CN103446403 A CN 103446403A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- radix
- herba
- medicine preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine preparation for treating a polycystic ovarian syndrome. According to the traditional Chinese medicine, the polycystic ovarian syndrome belongs to the domains of 'delayed menorrhea', 'hypomenorrhea', 'amenorrhea', 'infertility' and the like and has the main characteristics of deficiency of yin and blood, spleen dysfunction due to dampness, deficiency and decline of kidney yang and blood stasis block. According to the preparation, traditional Chinese medicines with the effects of tonifying kidneys and spleen, clearing and activating the channels and collaterals, eliminating dampness and eliminating phlegm, and clearing heat and eliminating dieresis, including root of Cynanchum inamoenum, morinda officinalis, rhizoma tupistrae chinensis, rust-coloured crotalaria herb with root, allium macrostemon, akebiaquinata, Indian rorippa herb, procumbent urena root, Huashan alum root, pinellia ternate, sago frond, african marigold and horehound are used and decocted with water to obtain decoction. Clinical tests in the hospital show that the total effective rate can be up to 98.0% and much better than that of a control group.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, relate in particular to a kind of Chinese medicine preparation for the treatment of polycystic ovarian syndrome.
Background technology
Polycystic ovarian syndrome (PCOS) is that gynecological clinic is common, morbidity is many is the endocrine metabolism imbalance syndrome of polymorphism because of property, clinical manifestation, take Hyperandrogenism and chronic anovulation as main clinical characteristics, the bilateral ovaries of take is one group of syndrome as performance such as polycystic change, infertile, hirsutism, acne, obesity, menoxenia, is one of common gynecological disease.The western medical treatment polycystic ovary syndrome is mainly applied clomiphene, but has nearly half patient to fail gestation due to the Luteinized unruptured follicle phenomenon occurring, and the western medical treatment effect is not satisfactory.The present invention proves through clinical trial for many years, and the treatment by Chinese herbs polycystic ovarian syndrome has good effect, and side effect is little.
Summary of the invention
The Chinese medicine preparation that the purpose of this invention is to provide a kind of polycystic ovarian syndrome.The traditional Chinese medical science thinks that this disease surely belongs to the categories such as " delayed menstrual cycle ", " very few through measuring ", " amenorrhea ", " infertile ".Its main feature is deficiency of YIN-blood, spleen asthenia and dampness retention, kidney yang deficiency, stagnation of blood stasis.Therefore, treating this sick main principle is kidney and spleen invigorating, dredge the meridian passage, drying dampness to eliminate phlegm, clearing away heat and promoting diuresis.
The objective of the invention is to be achieved through the following technical solutions, the Chinese medicine preparation of this treatment polycystic ovarian syndrome is made by the Chinese medicine of following weight portion: Radix Tylophorae arenicolae 15-25 part, Radix Morindae Officinalis 5-15 part, Rhizoma Tupistrae Chinensis 15-25 part, Herba Crotalariae Ferrugineae 25-35 part, Bulbus Allii Macrostemonis 11-16 part, Caulis Akebiae 5-10 Fen, Herba Rorippae 25-35 part, Radix urenae procumbentis 15-20 part, Radix Symplocoris chinensis 10-20 part, Rhizoma Pinelliae 7-12 part, Folium Cycadis Revolute 15-25 part, Flos Tagetis Erectae 5-15 part, Herba lagopsis supinae 15-20 part.
Preferably, 20 parts of Radix Tylophorae arenicolaes, 10 parts of Radix Morindae Officinaliss, 20 parts of Rhizoma Tupistrae Chinensis, 30 parts of Herba Crotalariae Ferrugineaes, 13 parts of Bulbus Allii Macrostemonis, Caulis Akebiae 8 30 parts of Fen, Herba Rorippae, 17 parts of Radix urenae procumbentis, 15 parts of Radix Symplocoris chinensiss, 9 parts of the Rhizoma Pinelliaes, 20 parts of Folium Cycadis Revolutes, 10 parts of Flos Tagetis Erectaes, 18 parts of Herba lagopsis supinaes.
Preparation method is made decoction by above-mentioned Chinese medicine decocting.
In side: Radix Tylophorae arenicolae kidney and spleen invigorating, removing toxic substances; Radix Morindae Officinalis kidney-replenishing, wind-damp dispelling; The Rhizoma Tupistrae Chinensis nourishing yin and purging fire, promoting blood flow to regulate menstruation; Herba Crotalariae Ferrugineae invigorating the spleen and replenishing QI, diuretic antiinflammatory; The Bulbus Allii Macrostemonis activating YANG and eliminating stagnation, the circulation of qi promoting intestinal stasis relieving; The Caulis Akebiae clearing away heat and promoting diuresis, blood circulation and channel invigorating; The Herba Rorippae clearing away heat and promoting diuresis, promoting blood circulation to restore menstrual flow; The Radix urenae procumbentis spleen invigorating is dried, and blood stasis dispelling is invigorated blood circulation; Radix Symplocoris chinensis, Rhizoma Pinelliae clearing away heat-damp and promoting diuresis, drying dampness to eliminate phlegm, dissolving lump and resolving mass; Folium Cycadis Revolute vital energy regualting and blood circulation-promoting suppressing the hyperactive liver; Flos Tagetis Erectae is enriched blood and is stimulated the menstrual flow, promoting tissue regeneration by removing blood stasis; The Herba lagopsis supinae blood circulation promoting and blood stasis dispelling.
Clinical data
1, physical data is originally organized 100 examples and is outpatients of gynecology, by table of random number, case is equally divided into to treatment group and matched group at random.19～40 years old treatment group age, average 28.3 years old, the course of disease 4～8 years.The matched group age is 20～40 years old, average 28.6 years old, and the course of disease 4～8 years.Two groups of patients compare aspect age, the course of disease, and no significant difference (P>0.05), have comparability.
2, rare ovum or the anovulation sent a manuscript to the compositor of diagnostic criteria (1); (2) clinical manifestation of excessive androgen and/or excessive androgen mass formed by blood stasis; (3) ultrasonic findings is polycystic ovary (side or bilateral ovaries have the follicle that 12 above diameters are 2-9mm, and/or Ovarian Volume is greater than 10m1).
3, the Therapeutic Method treatment group is taken Chinese medicine preparation of the present invention, takes Radix Tylophorae arenicolae 20g, Radix Morindae Officinalis 10g, Rhizoma Tupistrae Chinensis 20g, Herba Crotalariae Ferrugineae 30g, Bulbus Allii Macrostemonis 13g, Caulis Akebiae 8g, Herba Rorippae 30g, Radix urenae procumbentis 17g, Radix Symplocoris chinensis 15g, Rhizoma Pinelliae 9g, Folium Cycadis Revolute 20g, Flos Tagetis Erectae 10g, Herba lagopsis supinae 18g.Decocting becomes decoction, and potion, divided and sooner or later took for 2 times every day; Matched group takes marvelon tablet (every containing 0.15mg desogestrel and 0.03mg ethinylestradiol, Dutch Ou Jianong company product), 1 of every day, serve on 21 days after drug withdrawal, treat that next menstrual cycle works the clothes that continue on the 1st day.Two groups one month is a course for the treatment of, treats continuously 3 courses for the treatment of.
4, criterion of therapeutical effect recovery from illness: the menstrual cycle rule, basal body temperature is two-phase, ovary<1/4 uterine volume, atretic follicle number<3, or become pregnant successfully.Produce effects: basal body temperature is two-phase, LH/FSH<2.5 or ovary<1/4 uterine volume, and the maximum cross section area of ovary is dwindled and Follicle number reduces>1/2.Effectively: basal body temperature is the two-phase that is not true to type, and low-temperature phase extends or high-temperature-phase has fluctuation, the maximum cross section area of ovary is dwindled and Follicle number reduce>1/3 and≤1/2.Invalid: symptom is without improving or increasing the weight of.
5, after two groups of therapeutic effect treatment two courses for the treatment of curative effect relatively, treatment group 50 examples, wherein cure 30 examples (60%); Produce effects 11 examples (22%), effective 8 examples (16%), invalid 1 example (2%), total effective rate 98%; Matched group 50 examples, wherein cure 18 examples (36%); Produce effects 10 examples (20%), effective 13 examples (26%), no effect 9 (18%), total effective rate 82%.Two groups relatively, and treatment group cure rate, total effective rate obviously are better than matched group, have comparability.P＜0.05。
6, model case patient, the female, 27 years old, married, first visit in March, 2011.15 years of patient are through menophania, the cycle (my god) be 5～6/30, measure medium, painless warp.Patient's menstruation is gone in 3 months, under zona pellucida, surveys continuously that 2 of basal body temperatures are monthly is single-phase, purplish tongue, hesitant pulse.Chemical examination seminal fluid in the bridegroom's or husband's side is without extremely.Gynecologial examination: palace body anteposition, smaller.B ultrasonic is visited and the uterus size is 4cm * 3cm * 3cm, left ovary 3.1cm * 2.9cm, right ovary 4.1cm * 3cm.Serum hormone is measured, LH30.5mIU/m1, FSH10.1mIU/m1.Western medicine diagnose: polycystic ovarian syndrome.Patient's capable menstruation in 3 months, therefore treatment first takes medroxyprogestetone acetate 5 days, every day, 10mg, occurred that the 5th day of withdrawal bleeding starts to take traditional Chinese medicine.Prescription: take Radix Tylophorae arenicolae 20g, Radix Morindae Officinalis 10g, Rhizoma Tupistrae Chinensis 20g, Herba Crotalariae Ferrugineae 30g, Bulbus Allii Macrostemonis 13g, Caulis Akebiae 8g, Herba Rorippae 30g, Radix urenae procumbentis 55g, Radix Symplocoris chinensis 15g, Folium Cycadis Revolute 20g, Flos Tagetis Erectae 10g, Herba lagopsis supinae 18g.Decocting becomes decoction, and potion, divided and sooner or later took for 2 times every day.After taking 30 doses, menstruation can be risen voluntarily, then nurses one's health 2 months, and the 3rd menstrual phase is in the time of 50 days, and B ultrasonic shows that follicular development is to 1.5cm, uterus size 5.2cm * 4.2cm * 3.2cm.Continue and use above-mentioned Chinese medicine preparation, body temperature rise after 3 days, after medicine, body temperature is still 37.1 ℃, advises it to be HCG and detects, and result is positive, and B ultrasonic shows that blastular is in utero, about 1.5cm * 1.7cm size.
The specific embodiment
Embodiment mono-: take Radix Tylophorae arenicolae 20g, Radix Morindae Officinalis 10g, Rhizoma Tupistrae Chinensis 20g, Herba Crotalariae Ferrugineae 30g, Bulbus Allii Macrostemonis 13g, Caulis Akebiae 8g, Herba Rorippae 30g, Radix urenae procumbentis 17g, Radix Symplocoris chinensis 15g, Rhizoma Pinelliae 9g, Folium Cycadis Revolute 20g, Flos Tagetis Erectae 10g, Herba lagopsis supinae 18g, above-mentioned Chinese medicine decocting is become to decoction.
Embodiment bis-: take Radix Tylophorae arenicolae 15g, Radix Morindae Officinalis 5g, Rhizoma Tupistrae Chinensis 25g, Herba Crotalariae Ferrugineae 25g, Bulbus Allii Macrostemonis 16g, Caulis Akebiae 5g, Herba Rorippae 35g, Radix urenae procumbentis 20g, Radix Symplocoris chinensis 20g, Rhizoma Pinelliae 12g, Folium Cycadis Revolute 15g, Flos Tagetis Erectae 15g, Herba lagopsis supinae 15g, above-mentioned Chinese medicine decocting is become to decoction.
Embodiment tri-: take Radix Tylophorae arenicolae 25g, Radix Morindae Officinalis 15g, Rhizoma Tupistrae Chinensis 15g, Herba Crotalariae Ferrugineae 35g, Bulbus Allii Macrostemonis 11g, Caulis Akebiae 10g, Herba Rorippae 25g, Radix urenae procumbentis 15g, Radix Symplocoris chinensis 10g, Rhizoma Pinelliae 7g, Folium Cycadis Revolute 25g, Flos Tagetis Erectae 5g, Herba lagopsis supinae 20g, above-mentioned Chinese medicine decocting is become to decoction.
Claims (2)
1. a Chinese medicine preparation for the treatment of polycystic ovarian syndrome, is characterized in that this Chinese medicine preparation made by the Chinese medicine of following weight portion: Radix Tylophorae arenicolae 15-25 part, Radix Morindae Officinalis 5-15 part, Rhizoma Tupistrae Chinensis 15-25 part, Herba Crotalariae Ferrugineae 25-35 part, Bulbus Allii Macrostemonis 11-16 part, Caulis Akebiae 5-10 part, Herba Rorippae 25-35 part, Radix urenae procumbentis 15-20 part, Radix Symplocoris chinensis 10-20 part, Rhizoma Pinelliae 7-12 part, Folium Cycadis Revolute 15-25 part, Flos Tagetis Erectae 5-15 part, Herba lagopsis supinae 15-20 part.
2. a kind of Chinese medicine preparation for the treatment of polycystic ovarian syndrome according to claim 1, is characterized in that this Chinese medicine preparation made by the Chinese medicine of following weight portion: 20 parts of Radix Tylophorae arenicolaes, 10 parts of Radix Morindae Officinaliss, 20 parts of Rhizoma Tupistrae Chinensis, 30 parts of Herba Crotalariae Ferrugineaes, 13 parts of Bulbus Allii Macrostemonis, Caulis Akebiae 8 30 parts of Fen, Herba Rorippae, 17 parts of Radix urenae procumbentis, 15 parts of Radix Symplocoris chinensiss, 9 parts of the Rhizoma Pinelliaes, 20 parts of Folium Cycadis Revolutes, 10 parts of Flos Tagetis Erectaes, 18 parts of Herba lagopsis supinaes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310422291.9A CN103446403B (en) | 2013-09-07 | 2013-09-07 | Traditional Chinese medicine preparation for treating polycystic ovarian syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310422291.9A CN103446403B (en) | 2013-09-07 | 2013-09-07 | Traditional Chinese medicine preparation for treating polycystic ovarian syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103446403A true CN103446403A (en) | 2013-12-18 |
| CN103446403B CN103446403B (en) | 2014-12-17 |
Family
ID=49729516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310422291.9A Expired - Fee Related CN103446403B (en) | 2013-09-07 | 2013-09-07 | Traditional Chinese medicine preparation for treating polycystic ovarian syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103446403B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167850A (en) * | 2007-10-20 | 2008-04-30 | 徐究竟 | Medicine for treating polycystic ovary syndrome and preparation technology thereof |
| CN102302668A (en) * | 2011-09-13 | 2012-01-04 | 上海泰坤堂中医医院有限公司 | Pharmaceutical composition for treating polycystic ovary syndrome (PCOS) |
| CN102895456A (en) * | 2011-07-25 | 2013-01-30 | 刘艳萍 | Drug for treating polycystic ovarian syndrome |
-
2013
- 2013-09-07 CN CN201310422291.9A patent/CN103446403B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167850A (en) * | 2007-10-20 | 2008-04-30 | 徐究竟 | Medicine for treating polycystic ovary syndrome and preparation technology thereof |
| CN102895456A (en) * | 2011-07-25 | 2013-01-30 | 刘艳萍 | Drug for treating polycystic ovarian syndrome |
| CN102302668A (en) * | 2011-09-13 | 2012-01-04 | 上海泰坤堂中医医院有限公司 | Pharmaceutical composition for treating polycystic ovary syndrome (PCOS) |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103446403B (en) | 2014-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101919953B (en) | Traditional Chinese medicine combination menstruation-regulating soup for treating polycystic ovary syndrome | |
| CN101342353A (en) | Traditional Chinese medicine preparation for treating barrenness and preparation method thereof | |
| CN101085299A (en) | Traditional Chinese medicinal composition for treating female pelvic inflammation and its application | |
| CN103393989B (en) | Traditional Chinese medicine composition for treating gynecologic inflammation | |
| CN103638262A (en) | Gynecological hemostatic capsule | |
| CN101744915B (en) | Medicament for treating maternal-fetal ABO incompatibility | |
| CN103349766A (en) | Pharmaceutical composition for endless postpartum lochia | |
| CN103432419A (en) | Traditional Chinese medicinal composition for treating dysfunctional uterine bleeding and preparation method of preparation thereof | |
| CN103585574B (en) | Traditional Chinese medicine composition for treating polycystic ovary syndrome | |
| CN103263650B (en) | Chinese medicament for conditioning female menstruation | |
| CN102580050A (en) | Externally applied traditional Chinese medicine combination for treating chronic pelvic inflammatory disease through applying iontophoresis and preparation method | |
| CN103446403B (en) | Traditional Chinese medicine preparation for treating polycystic ovarian syndrome | |
| CN104001146A (en) | Traditional Chinese medicine composition for curing dysmenorrhea | |
| CN103816325A (en) | Traditional Chinese medicine preparation for early-stage breast cancer | |
| CN105267925A (en) | Medicine for treating postpartum pelvic blood stagnation and method for preparing medicine | |
| CN101912511B (en) | Chinese medicinal preparation for treating qi-blood deficiency polycystic ovary syndrome | |
| CN105250975A (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof | |
| CN103239690B (en) | Traditional Chinese medicine composition for nursing and treating hyperplasia of mammary glands | |
| CN104644956A (en) | Traditional Chinese medicine composition for treating cold congealing and blood stasis type dysmenorrheal and preparation method thereof | |
| CN104001054A (en) | Traditional Chinese medicine for treating metrorrhagia and metrostaxis | |
| CN104173981A (en) | Medical decoction for treating uterine fibroids and hypertrophy of uterus and preparation method thereof | |
| CN103169824A (en) | Traditional Chinese medicine composition for treating menoxenia infertility and application thereof | |
| CN104435362B (en) | A kind of Chinese medicine composition for the treatment of chronic pelvic inflammatory disease | |
| CN108478768A (en) | Menses must lead to Chinese medicine preparation | |
| CN103611027A (en) | Pharmaceutical composition for clinically preventing, nursing and treating trichomonas vaginitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: WANG QINGFANG Free format text: FORMER OWNER: MA YULING Effective date: 20141117 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Qingfang Inventor after: Zhang Xingling Inventor before: Ma Yuling Inventor before: Zhang Yuhua Inventor before: Zhang Meifen |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: MA YULING ZHANG YUHUA ZHANG MEIFEN TO: WANG QINGFANG ZHANG XINGLING |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20141117 Address after: 262600 Wolong branch of Xin Zhai Center Hospital of Linqu County, Weifang, Shandong Applicant after: Wang Qingfang Address before: The 262600 Shandong city of Weifang province Linqu County Road No. 21 people's Hospital of Linqu County Applicant before: Ma Yuling |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141217 Termination date: 20150907 |
|
| EXPY | Termination of patent right or utility model |